When Mist Becomes Most

Prof Burt from Chicago has presented "At the Limits 2018"
and shown the headline results of the MIST trial (A randomised, assessor blinded clinical trial), which finished recruitment in 2016. 

Very Interesting, but you'll have to wait until the results are announced/published before we will . Sorry but it is only fair to the USA, British,Swedish and Brazilian Teams to keep quiet.

However, before he started talking about the results, in his own words “Don’t do Progressive disease”

People with active disease respond best to this treatment which is cyclophosphamide and anti-thymocyte globulin followed by stem cells to block the infection risk of loss of neutrophils.

Next up is the Trial. Maximizing Outcome of Stem Cell Transplantation (MOST), We look forward to seeing what is planned.